Fig. 3

DC-34 silencs MYC expression in cancer cells. a Inhibition of L363 MM cell proliferation at 24 (IC₅₀ = 3.4 µM) (red), 48 (IC₅₀ = 3.4 µM) (green) and 72 h (IC₅₀ = 3.1 µM) (blue). b Inhibition of MYC protein translation with 5 μM of DC-34 is sustained over time in L363 cells. c The half maximal inhibitory concentration (IC₅₀) of DC-34 with respect to MYC protein inhibition as determined by Peggy protein expression. d A Western blot of MYC protein during a representative cycloheximide-chase degradation experiment with L363 multiple myeloma cells. Cells were treated with 10 µg/mL of cycloheximide (CX) in the absence or presence of DC-34 (5 µM) and MYC protein expression was assessed at indicated time points. β-actin was used as loading control. e MYC protein levels are inhibited as a function of the dose of DC-34 in L363 cells; only the highest dose of DC-34 affected MYC in the more resistant CA46 Burkitt’s lymphoma cells. f Western blot analysis of 293T cells transiently transfected with either GFP or CMV-MYC plasmid (the CMV promoter lacks a MYC G4) (right) and dosed with different concentrations of DC-34. All western blots were exposed for <1 min